Moderator: Lisa G. Pont, PhD – Discipline of Pharmacy, University of Technology Sydney, Sydney, NSW, Australia
### @@@ Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida ### 1063291###Moderator###PhD Student###University of Florida###Moderator: Sebastian Jugl, BPharm, RPh (he/him/his) – University of Florida
### he/him/his OP1-0Moderator: Marie Louise L. De Bruin, PhD (she/her/hers) – Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University
### she/her/hers @@@ Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University ### 1062566###Moderator###Assistant Professor###McGill University###Moderator: Michael Andrew Webster-Clark, PharmD, PhD (he/him/his) – McGill University
### he/him/his OP2-0Moderator: Freyja Jonsdottir, MSc (she/her/hers) – Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavík, Iceland; Hospital Pharmacy Landspítali–The National University Hospital, Reykjavík, Iceland
### she/her/hers @@@ Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet ### 1932107###Moderator###Postdoctoral Researcher###Karolinska Institutet###Moderator: Jessica C. Young, PhD (she/her/hers) – Karolinska Institutet
### she/her/hers OP3-0Moderator: Deborah Layton, PhD, FISPE – PEPI Consultancy Limited
### @@@ Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway ### 1062978###Moderator###PhD candidate###School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway###Moderator: Claudia Bruno, BSc(hon) (she/her/hers) – School of Population Health, University of New South Wales; Department of Chronic Diseases, Norwegian Institute of Public Health, Oslo, Norway
### she/her/hers OP4-0